MD Anderson, Pfizer Launch Immuno-Oncology Collaboration

The University of Texas MD Anderson Cancer Center will join with Pfizer to study novel combinations of three of the pharma giant’s immuno-oncology candidates and other Pfizer treatments for solid and blood cancers, the partners said today, through a collaboration whose value was not disclosed.The collaboration will consist of multiple studies—the first of which is envisioned to enroll up to 188 patients with solid tumors , who will be placed in seven different treatment groups of imm